Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Arthritis, Rheumatoid, Date of authorisation: 16/12/2019, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, Breast Neoplasms, Date of authorisation: 04/03/2013, Revision: 22, Status: Authorised

Shortage of Abraxane (paclitaxel)

Human medicines European public assessment report (EPAR): Lupkynis, voclosporin, Lupus Nephritis, Date of authorisation: 15/09/2022, Revision: 2, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): zuranolone, decision type: , therapeutic area: , PIP number: P/0358/2022

Human medicines European public assessment report (EPAR): NovoMix, insulin aspart, Diabetes Mellitus, Date of authorisation: 01/08/2000, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Enjaymo, sutimlimab, Hemolysis;Anemia, Hemolytic, Autoimmune, Date of authorisation: 15/11/2022, Revision: 3, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Enmetazobactam,cefepime, decision type: , therapeutic area: , PIP number: P/0340/2022

Human medicines European public assessment report (EPAR): Actos, pioglitazone, Diabetes Mellitus, Type 2, Date of authorisation: 13/10/2000, Revision: 30, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Imcivree,Setmelanotide, decision type: , therapeutic area: , PIP number: P/0348/2022